Research
Hormonal
Patient choice is key to realizing the benefits of lipid-lowering interventions.
Encouraging patient involvement in treatment decisions can enhance adherence and outcomes.
StrongSupportsmedium confidence
As long-term adherence to treatment is required patient choice is key to realizing the benefits of these interventions.
Why this rating
The claim is based on the importance of adherence in treatment outcomes.
Source
Prioritizing health outcomes in a limited world
Nadeem Qureshi et al. · Current Opinion in Lipidology · 2015
DOI 10.1097/mol.0000000000000170
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Modern systematic evidence assessment and economic appraisal favour the use of lipid-lowering drugs especially statins at higher doses than currently prescribed in secondary prevention.Strong
- A fixed-dose drug treatment protocol is recommended for the management of patients in secondary prevention, diabetes, and primary prevention.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →